UK CMA ' s Write-up of PacBio Acquisition by Illumina Makes for XXX Reading; Clearly They Believe XXX and XXX

After writing my two recent pieces on the business side of the long read industry I planned, after a recent extended family vacation, to try to get back to science.   Particularly after my chagrin when various correspondents pointed out a fact from each I should have found and didn't:in my ONT pieceI failed to discover that ONT has two share classes and the Woodford fund's shares cannot be used to gain control of the company and in thePacBio piecethat there is a $100M breakup fee due PacBio if for any reason the deal doesn't go thru.   I'm particularly red faced on that one, as a breakup fee would play importantly into PacBio's financial health should the deal go south; $100M would buy perhaps two quarters time.But then a bunch of people threw my way theUK Competition and Mergers Authority (CMA) report on the merger and I foolishly opened the document.   It makes for interesting reading, but that is hampered by the fact it is highly redacted -- like my title. Reserving the right to comment on the contents substance at a future date (or never), I'd just like to give a tour around some of the redactions.Read more »
Source: Omics! Omics! - Category: Bioinformatics Authors: Source Type: blogs